COMPANY
Levity Inc. dba Levity
Levity Inc. dba Levity: warning letter recipient for Liraglutide, Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Liraglutide | False & Misleading Claims/Misbranded (Telehealth), 2026-02-20 Regulator FDA warning letters |
|---|---|
| Semaglutide | False & Misleading Claims/Misbranded (Telehealth), 2026-02-20 Regulator FDA warning letters |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.